Loyal Valley Capital Leads USD100m Series B for Chinese Ophthalmology Company Arctic Vision

Source(s): DealStreetAsia

Loyal Valley Capital led a USD100m Series B for Arctic Vision, a China-based clinical-stage ophthalmology company focused on developing therapies for pan-ocular diseases, with participation from Tencent, Octagon Capital, and New World Development Group CEO Dr. Adrian Cheng, and follow-on from Nan Fung Life Sciences, Pivotal bioVenture Partners China and Morningside Ventures. Read more